CSLLY - uniQure gains after selling portion of royalty interest due from CSL

2023-05-15 08:26:38 ET

Dutch biotech uniQure N.V. ( NASDAQ: QURE ) added ~7% pre-market Monday after announcing an agreement to sell a portion of royalty rights expected to receive from Australian drugmaker CSL Limited ( OTCQX:CSLLY ) in relation to the gene therapy Hemgenix.

The agreement with HealthCare Royalty (HCRx) and Sagard Healthcare has a gross purchase price of up to $400M in cash depending on global net sales of HEMGENIX, which is approved in the U.S. Europe and the U.K. for hemophilia B.

In May 2021, CSL’s ( OTCQX:CSLLY ) CSL Behring unit inked an exclusive global license and commercialization agreement with uniQure ( QURE ) for Hemgenix.

Per the terms of the deal with HealthCare Royalty (HCRx) and Sagard, subject to certain conditions, uniQure ( QURE ) is entitled to $375 upfront cash in exchange for the lowest royalty tier on CSL Behring’s worldwide net sales of Hemgenix.

uniQure ( QURE ) said that the transaction will extend its cash runway into Q2 2026, and the partners agreed to close the deal within 15 business days from signing.

More on uniQure

• uniQure inks licensing deal for gene therapy candidate targeting ALS
• uniQure: An FDA Approval, An Advancing Pipeline And A Critical Data Readout

For further details see: